CLEVELAND, OH – January 26, 2017


Allinaire Therapeutics, a respiratory therapeutics start-up launched by BioMotiv, has recently received new investments from BioCrossroads’ Indiana Seed Fund and Indiana University’s Innovate Indiana Fund. The Funding will advance the development of therapeutics for the treatment of chronic obstructive pulmonary disorder (COPD) and other respiratory diseases.

Allinaire Therapeutics is based on intellectual property from the Indiana University School of Medicine, developed by scientific founders Irina Petrache, MD, a Harrington Scholar-Innovator, and Matthias Clauss, PhD.

Click here to read more.